Newron's Shareholders with an overwhelming majority vote in favo

Newron's Shareholders with an overwhelming majority vote in favour of
NeuroNova acquisition

Milan, Italy - 5 December 2012 - Newron Pharmaceuticals S.p.A. ("Newron", SIX:
NWRN), a research and development company focused on Central Nervous System
(CNS) and pain therapies, announces that at its Shareholder's Meeting held
today, 5 December 2012, in Zurich, all motions on the agenda were accepted:

  *Increase in the share capital, to be subscribed via contribution in kind
    of shares of NeuroNova AB, a condition precedent to the acquisition of
    NeuroNova AB;
  *Revocation of the increase in the Company's share capital resolved by the
    shareholders' meeting on 28 June 2012;
  *Amendment of the number of the members of the Board of Directors from 6 up
    to 7, appointment of a director as proposed by NeuroNova AB current
    shareholders and determination of his relevant remuneration.

The shareholders elected Jakob Lindberg to the Board of Directors. Jakob
Lindberg joined the Investor Growth Capital Europe team in 2005. He focuses
primarily on investments in the healthcare sector.*

At the Shareholders's meeting 3,767,962 shares of the company's total capital
of 8,796,332 shares, or 40.84%, were represented. The acquisition was approved
by 100% of the represented shares.

Rolf Stahel, Chairman of Newron, said: "We are grateful to our shareholders
for voting in favour of all motions. The revised agreement to acquire
NeuroNova experienced strong support both from institutional and retail
shareholders demonstrating clearly that there is trust and support in Newron's
strategy to broaden its development pipeline, its cash position and
shareholder base."

Stefan Weber, CEO of Newron, said: "Safinamide stays our main priority as it
is our key value driver. Our team is working to expedite the global filing of
the compound, together with our partners, Zambon and Meiji. With this
acquisition we can now broaden our pipeline. The new funds raised in August
and those available through the acquisition of NeuroNova will allow us to
develop other novel compounds in our pipeline to the next value creation
point, including the two NeuroNova projects. We are truly excited by the trust
that our shareholders have put in management's strategy. The entire management
looks forward to combining NeuroNova's highly innovative pipeline products
with Newron's demonstrated developmental and regulatory expertise."

* In addition, Jakob Lindberg is the CEO of Oncopeptides, a pharmaceutical
company working to develop more effective chemotherapeutic treatments for
cancer. Prior to joining Investor Growth Capital, he worked at McKinsey &
Company and was the co-founder and CEO of Cellectricon, a Swedish company
developing functional, cell-based screening devices for drug discovery. Jakob
Lindberg is a licensed Swedish physician with an M.D. and Medical Licentiate
thesis from the Karolinska Institute, and a B.A. in Finance from Stockholm

About Newron Pharmaceuticals

Newron (SIX: NWRN) is a biopharmaceutical company focused on novel therapies
for diseases of the Central Nervous System (CNS) and pain. The Company is
headquartered in Bresso near Milan, Italy. Phase III trials of safinamide for
the treatment of Parkinson's disease (PD) have been completed earlier in 2012.
Based on the phase III results of safinamide, Newron is working to expedite
the global filing of the compound, together with its partners. Zambon Group
has the rights to commercialise safinamide globally, excluding Japan and other
key Asian territories, and Meiji Seika has the rights to develop and
commercialise safinamide in Japan and other key Asian territories. Newron's
additional projects are primarily addressed towards highly promising rare
diseases and are at various stages of preclinical and clinical development,
including sarizotan for Rett's syndrome, ralfinamide for specific pain
indications, and NW-3509 as potential first add-on therapy for the treatment
of schizophrenia.

For more information, contact:

Media                       Investors and analysts

Stefan Weber - CEO

Phone: +39 02 6103 46 26


UK/Global media
                            Stefan Weber - CEO
Julia Phillips
                            Phone: +39 02 6103 46 30
FTI Consulting
Phone: +44 (0) 20 7269 7187


Martin Meier-Pfister

IRF Communications

Phone: +41 43 244 81 40

Important Notices

This document contains forward-looking statements, including (without
limitation) about (1) Newron's ability to develop and expand its business,
successfully complete development of its current product candidates and
current and future collaborations for the development and commercialisation of
its product candidates and reduce costs (including staff costs), (2) the
market for drugs to treat CNS diseases and pain conditions, (3) Newron's
anticipated future revenues, capital expenditures and financial resources, and
(4) assumptions underlying any such statements. In some cases these statements
and assumptions can be identified by the fact that they use words such as
"will", "anticipate", "estimate", "expect", "project", "intend", "plan",
"believe", "target", and other words and terms of similar meaning. All
statements, other than historical facts, contained herein regarding Newron's
strategy, goals, plans, future financial position, projected revenues and
costs and prospects are forward-looking statements.

By their very nature, such statements and assumptions involve inherent risks
and uncertainties, both general and specific, and risks exist that
predictions, forecasts, projections and other outcomes described, assumed or
implied therein will not be achieved. Future events and actual results could
differ materially from those set out in, contemplated by or underlying the
forward-looking statements due to a number of important factors. These factors
include (without limitation) (1) uncertainties in the discovery, development
or marketing of products, including without limitation negative results of
clinical trials or research projects or unexpected side effects, (2) delay or
inability in obtaining regulatory approvals or bringing products to market,
(3) future market acceptance of products, (4) loss of or inability to obtain
adequate protection for intellectual property rights, (5) inability to raise
additional funds, (6) success of existing and entry into future collaborations
and licensing agreements, (7) litigation, (8) loss of key executive or other
employees, (9) adverse publicity and news coverage, and (10) competition,
regulatory, legislative and judicial developments or changes in market and/or
overall economic conditions.

Newron may not actually achieve the plans, intentions or expectations
disclosed in forward-looking statements and assumptions underlying any such
statements may prove wrong. Investors should therefore not place undue
reliance on them. There can be no assurance that actual results of Newron's
research programmes, development activities, commercialisation plans,
collaborations and operations will not differ materially from the expectations
set out in such forward-looking statements or underlying assumptions.

Newron does not undertake any obligation to publicly up-date or revise forward
looking statements except as may be required by applicable regulations of the
SIX Swiss Exchange where the shares of Newron are listed.

This document does not contain or constitute an offer or invitation to
purchase or subscribe for any securities of Newron and no part of it shall
form the basis of or be relied upon in connection with any contract or
commitment whatsoever.

Media Release (PDF)

Provider                  Channel         Contact
Tensid Ltd., Switzerland      Provider/Channel related enquiries   
                                          +41 41 763 00 50
Press spacebar to pause and continue. Press esc to stop.